Avalyn Pharma Inc is a clinical-stage biopharmaceutical company based in Seattle, WA, specializing in the development of targeted therapies for rare respiratory diseases. Their focus lies in the treatment of interstitial lung diseases, including idiopathic pulmonary fibrosis, with their lead candidate, AP01, being a Phase 2b-ready inhaled formulation of pirfenidone.
With a strong emphasis on improving patient quality of life, Avalyn Pharma is dedicated to developing inhaled formulations of approved medications to address the unmet needs of individuals suffering from rare lung diseases. Their innovative approach and recent advancements in clinical development have positioned them as a key player in the field of respiratory therapeutics.
Generated from the website